Furthermore, a randomized phase 2 study in platinum-resistant high-grade serous ovarian cancer patients showed that addition of the ATR inhibitor berzosertib to gemcitabine provided benefits in terms of progression-free survival [58]. Here, ATR is linked to ovarian serous adenocarcinoma.